Our acapreneurial strategy has enabled us to forge fruitful partnerships with biotechnology companies, including the following:
Currently on the market
Boehringer Ingelheim’s blood thinner dabigatran etexilate (Pradaxa®) was pioneered in clinical trials administered through LIMR. A collaboration funded by the company also promised to extend the drug’s use to cancer patients.
In preclinical development
Genisphere, LLC collaborated with LIMR in the development of a therapy targeting the mRNA-binding protein HuR using 3DNA nano-carriers for treating ovarian cancer.
Dynamis Therapeutics, Inc.
Dynamis Therapeutics, Inc. is developing a small molecule drug for the treatment of diabetic complications and other autoimmune diseases. The drug was discovered in collaboration with LIMR scientists.
Telesis Therapeutics, Inc.
Telesis Therapeutics, Inc. is developing a small molecule cancer drug discovered at LIMR.
ProActive HealthSciences is developing a method to treat esophageal cancer based on studies done at LIMR.